Medicine and Dentistry
Peptide Derivative
100%
Chronic Myelogenous Leukemia
75%
Angiogenesis
59%
Phosphotransferase
56%
Antiangiogenic Activity
54%
Growth Regulation
50%
Biological Product
50%
Chronic Myelogenous Leukemia
50%
Imatinib
50%
Fk 506 Binding Protein
50%
Secretion (Process)
50%
P21
50%
Mantle Cell Lymphoma
50%
Cyclin D1
50%
Limonene
50%
In Vitro
49%
Protein Tyrosine Kinase
43%
Cell Line
32%
Western Blot
32%
Disease Exacerbation
30%
Diseases
30%
Small Interfering RNA
27%
Programmed Cell Death
25%
Endothelial Cell
24%
Tumor Xenograft
20%
Antiangiogenic Therapy
20%
Receptor
14%
Antiangiogenic
14%
Cell Migration
14%
Tumor Cell
13%
Nephroblastoma Overexpressed Protein
12%
Hematopoietic Stem Cell
12%
BCR ABL Protein
12%
Cell Signaling Pathway
12%
Tumor Suppressor Gene
12%
Chronic Myeloid Leukemia Cell Line
12%
Solid Malignant Neoplasm
12%
down Regulation
12%
Microvessel
10%
Docetaxel
10%
Cyclin Dependent Kinase Inhibitor
10%
Polymerase Chain Reaction
10%
Ex Vivo
10%
Cell Surface Receptor
10%
CYR61
10%
Matrigel
10%
Non-Hodgkin Lymphoma
10%
Mantle Cell Lymphoma Cell Line
10%
Cancer
10%
Cell Cycle
10%
Biochemistry, Genetics and Molecular Biology
CD44
100%
Myeloid
87%
Angiogenesis
59%
Kinase
58%
Phosphotransferase
58%
Antiangiogenic Activity
54%
Imatinib
54%
Cyclin D1
50%
Growth Regulation
50%
P21
50%
Secretion (Process)
50%
Binding Protein
50%
Receptor Tyrosine Kinase
45%
Tyrosine Kinase
33%
Western Blot
32%
Small Interfering RNA
27%
Signal Transduction
25%
CD34
20%
Cell Migration
14%
Eicosanoid Receptor
14%
Tumor Suppressor Gene
12%
Northern Blotting
12%
Tyrosine
12%
Hematopoietic Stem Cell
12%
down Regulation
12%
Polymerase Chain Reaction
10%
Cell Surface Receptor
10%
Rat Model
10%
Neovascularization (Pathology)
10%
Cyclin-Dependent Kinase
10%
Isoform
10%
CYR61
10%
Mouse Model
10%
Intravital Microscopy
10%
Cell Cycle
10%
Amino Acids
10%
Mouse
10%
Actin
9%
Hematopoiesis
8%
Tyrosine Kinase Inhibitor
8%
K562 Cells
8%
Colony Formation
8%
Growth Inhibition
8%
Transfection
8%
Stem Cell
8%
Cell Growth
8%
Pharmacology, Toxicology and Pharmaceutical Science
Peptide Derivative
100%
Imatinib
87%
Chronic Myeloid Leukemia
87%
Phosphotransferase
75%
Protein Tyrosine Kinase
62%
Antiangiogenic
59%
Biological Product
50%
Fk 506 Binding Protein
50%
Neoplasm
38%
Small Interfering RNA
27%
Leukemogenesis
25%
Myeloid Leukemia
25%
Protein Tyrosine Kinase Inhibitor
25%
Antiangiogenic Therapy
20%
Receptor
14%
Solid Malignant Neoplasm
12%
BCR ABL Protein
12%
Nephroblastoma Overexpressed Protein
12%
Western Blot
12%
Tumor Suppressor Protein
12%
Matrigel
10%
Cell Surface Receptor
10%
Neovascularization (Pathology)
10%
Docetaxel
10%
Mouse Model
10%
Rat Model
10%
Mouse
10%
Amino Acid
10%
Intravital Microscopy
10%
Citrus
10%
Actin
9%
